Peptalk← All compounds

Metabolic & Weight Management

CagriSema

Also known as cagrilintide/semaglutide · cagri-sema · cagrilintide and semaglutide

Clinically studiedSubcutaneous injectionNot FDA-approved as of June 2026; investigational. Novo Nordisk submitted a New Drug Application to the U.S. FDA in December 2025, with review expected during 2026, and it is not approved in the EU. Cagrilintide is not a component of any FDA-approved drug and has not been found safe and effective, so compounding products containing cagrilintide is prohibited under federal law; the FDA has separately proposed excluding semaglutide from the 503B bulks list (part of the broader 2025-2026 wind-down of compounded GLP-1 medicines). Neither GLP-1 receptor agonists nor amylin analogues are specifically named on the current WADA Prohibited List, but athletes should verify status with their governing body.

CagriSema is an investigational fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, developed by Novo Nordisk for chronic weight management. The two components act through complementary appetite-regulating pathways: semaglutide engages GLP-1 signaling in vagal and hypothalamic circuits, while cagrilintide acts on amylin receptors in the area postrema, together reducing hunger and promoting satiety. It has been evaluated in the large phase 3 REDEFINE program in adults with overweight or obesity, with and without type 2 diabetes, where it produced substantial mean body-weight reductions over 68 weeks alongside improvements in glycemic and cardiometabolic markers. Because both components are studied human peptides assessed in randomized controlled trials, the research base is relatively robust, though the combination is not yet an approved drug. Novo Nordisk submitted a New Drug Application to the U.S. FDA in December 2025, with regulatory review anticipated during 2026.

Studied / used for

  • Investigated for chronic weight management in adults with overweight or obesity
  • Studied for weight reduction in adults with type 2 diabetes and overweight or obesity
  • Investigated for improvements in glycemic control (HbA1c) and prediabetes reversal
  • Studied for cardiometabolic markers including blood pressure, waist circumference, and lipid levels

Commonly reported side effects

  • Nausea commonly reported
  • Vomiting commonly reported
  • Constipation commonly reported
  • Diarrhea commonly reported
  • Abdominal pain commonly reported
Clinically studied. Supported by human clinical trials. This reflects the strength of the research base, not effectiveness or a recommendation.

Not medical advice.

This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.

← Back to all compounds